Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P08603: Variant p.Gln1076Glu

Complement factor H
Gene: CFH
Feedback?
Variant information Variant position: help 1076 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glutamine (Q) to Glutamate (E) at position 1076 (Q1076E, p.Gln1076Glu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (Q) to medium size and acidic (E) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In CFHD. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1076 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1231 The length of the canonical sequence.
Location on the sequence: help NAYIVSRQMSKYPSGERVRY Q CRSPYEMFGDEEVMCLNGNW The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         NAYIVSRQMSKYPSGERVRYQCRSPYEMFGDEEVMCLNGNW

Mouse                         NATIVTRTKNKYLHGDRVRYECNKPLELFGQVEVMCENGIW

Bovine                        NA-IIHNQKSKYQSEERARYECIGNYDLFGEMEVVCLNGTW

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 19 – 1231 Complement factor H
Domain 1046 – 1104 Sushi 18
Glycosylation 1095 – 1095 N-linked (GlcNAc...) asparagine
Disulfide bond 1048 – 1091
Alternative sequence 450 – 1231 Missing. In isoform 2.
Beta strand 1072 – 1077



Literature citations
Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition.
Richards A.; Buddles M.R.; Donne R.L.; Kaplan B.S.; Kirk E.; Venning M.C.; Tielemans C.L.; Goodship J.A.; Goodship T.H.J.;
Am. J. Hum. Genet. 68:485-490(2001)
Cited for: VARIANTS CFHD GLU-1076; GLY-1119 AND ARG-1184; Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site.
Perkins S.J.; Goodship T.H.J.;
J. Mol. Biol. 316:217-224(2002)
Cited for: VARIANTS AHUS1 MET-956; GLU-1076; GLY-1119; LEU-1183; ARG-1184; ARG-1189; LEU-1191; ASP-1194; ALA-1197; CYS-1210; GLY-1215 AND GLN-1215;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.